OTCQB:EMHTF - Post by User
Comment by
bluewhale01on Feb 16, 2018 2:03pm
124 Views
Post# 27573919
RE:RE:News Out
RE:RE:News Out
That's the $64,000 question. Identifying and patenting a CBD derivative for a preventative and/or mitigating treatment for Parkinson is still a long way from realizing a profit from sales of said treatment. This said, unlike most medical cannabis treatment applications which are more or less naturopathic in nature and thereby public domain, Emerald's patented compound will enjoy worldwide protection from competitors for a minimum of 10 years. Furthermore and unlike most cannabis treatments which are priced like a commodity, having patented the CBD compound, Emerald can charge what they like for the medication making it hugely profitable. So.. to answer your question.. if the efficacy of this CBD compound/treatment is statistically significant in the prevention and/or treatment of Parkinsons AND Emerald can execute on the marketing, distribution and sales of this CBD treatment, the impact on EMH will be profound as a revenue and profit stream and will also cement Emerald's position as a leader in proprietary, cannabis derived medications and therapies.